A personalized cancer immunotherapy combining custom mRNA vaccines with checkpoint inhibitor drugs has produced remarkable results in early-stage clinical trials, shrinking tumors in 78 percent of patients with previously treatment-resistant solid cancers. The approach, developed through a collaboration between Moderna and Merck, represents a potential paradigm shift in cancer treatment by training each patient's immune system to recognize and attack their specific tumor.
The therapy works by sequencing the DNA of a patient's tumor to identify unique mutations, then synthesizing an mRNA vaccine that encodes up to 34 of these tumor-specific neoantigens. When injected, the vaccine instructs the patient's cells to produce these abnormal proteins, triggering a targeted immune response. Combined with pembrolizumab, a checkpoint inhibitor that removes the "brakes" cancer cells place on the immune system, the approach generates a powerful, tumor-specific attack.
Trial Results
In a Phase 2 trial involving 200 patients with advanced melanoma, non-small cell lung cancer, and colorectal cancer, 78 percent experienced significant tumor shrinkage, with 34 percent achieving complete response — meaning no detectable cancer remained. Progression-free survival at one year was 73 percent, compared to 45 percent for checkpoint inhibitors alone.
"These results suggest we are approaching cancer treatment the way we should have all along — as a personalized immune challenge unique to each patient," said Dr. Stéphane Bancel, Moderna CEO. "Every tumor has a unique fingerprint of mutations, and now we can train the immune system to recognize that exact fingerprint."
The approach is currently limited by production timelines, as creating a personalized vaccine requires approximately six weeks from tumor biopsy to treatment initiation. Cost is also a significant consideration, with each personalized vaccine estimated at $100,000 to produce. However, the companies are investing in automation and manufacturing capacity to reduce both timelines and costs. Large-scale Phase 3 trials are underway across multiple cancer types, with results expected in 2027. If confirmed, the approach could eventually become a standard component of cancer treatment alongside surgery, radiation, and chemotherapy.